On August 20, Pingshan Translational Medicine Center (PTMC) and Sofro Biotech Co., Ltd. (Sofro) signed a strategic MOU on co-developing inhalation biotechnical R&D platform. Grounded on this platform, the two sides will carry out cooperative research including inhalation formulation, physicochemical properties, and drug delivery R&D.

Inhaled medication is one of the effective ways for treating diseases like asthma and chronic obstructive pulmonary disease (COPD).As statistics reveals, in China, asthma affects estimated 30 million people, with a morbidity of 4.1%. The impact of chronic obstructive pulmonary disease (COPD) is much severe, as it makes breathing difficult for 80 million people who develop it. To control the symptoms and allow the patients to live a more normal life, the WHO has suggested that inhaled medication to be used.

While inhalation is highly recommended to manage some diseases for its direct efficacy on the localized target organs via the lung and the vascular network of the body, the development and production of it can be difficult and highly expensive considering lots of factors like the dose distribution, drug delivery, inhaled air, prescription, the inhaler and so on.

The cooperation between PTMC and Sofro will leverage the strengths of both sides to promote the transformation of biomedical research based on this initiative to develop inhaled medications. In the future,the two parties will keep close industrial ties and seek to demonstrate an exemplary role for science and marketing innovation.